Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- LEN +3.8%, SFUN +0.8%
M&A news:
- PRXL +4% (to be acquired by Pamplona Capital Management for $88.10/share), .
Other news:
- LPCN +32.8% ( announces LPCN 1021 achieved primary endpoints confirming the efficacy of twice daily oral administration andgenerally met the pre-specified per dose secondary endpoints for twice daily oral administration)
- ENPH +19.1% (Enphase Energy enters into a Master License Agreement with Flextronics Industrial)
- BLCM +5.4% (continued strength)
- CFMS +4.7% (confirms it has received FDA 510(k) clearance of its primary iTotal Hip replacement system)
- EYEG +3.9% (indicated higher after Armistice Capital discloses 9.9% passive stake)
- TSLA +3.6% (reports nearing deal for China production plant)
- MRVL +3.1% (continued strength)
- DDD +2.3% (continued strength)
- AMD +2.1% (continued strength)
- ALXN +1.6% (CEO disclosed the purchase of 10K shares at avg price of $116.72/share)
- NVS +1.4% (reports Phase III study for RTH258 achieved the primary efficacy endpoint)
Analyst comments:
- VSLR +5.7% (upgraded to Buy from Neutral at Goldman)
- MRVL +3.1% (upgraded to Overweight from Sector Weight at Pacific Crest )
- FOSL +3% (upgraded to Neutral from Underperform at Buckingham Research)
- AVY +2.2% (upgraded to Buy from Neutral at BofA/Merrill)
- NVDA +0.8% (upgraded to Sector Weight from Underweight at Pacific Crest)
- KIM +0.7% (upgraded to Neutral from Sell at Goldman)
- COST +0.7% (upgraded to Buy from Neutral at Northcoast)